A Phase 4 interventional study of 20% albumin and Balanced salt solution in Cirrhosis, Liver, Acute-On-Chronic Liver Failure and Shock, Septic, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Active, not recruiting at 1 site in India. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh — 3 open to participants now, 6 under way, none of them phase 3. Liver Cirrhosis · Post Graduate Institute of Medical Education and Research, Chandigarh.
Among the 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2020, is the only one in phase 4, and was the 12th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →3 of the 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh are open now, in 1 country. Recruiting first, the newest first:
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
Post Graduate Institute of Medical Education and Research, Chandigarh · Sites in India
Ages 18–65
By country, each count listing its studies:
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 4 · Phase 4 1
First in 2016; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 141 across the 10 interventional studies, 142 across the 7 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Post Graduate Institute of Medical Education and Research, Chandigarh is the lead sponsor of 298 studies on the registry; 43 are open to participants now.
1 of the studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06095466Post Graduate Institute of Medical Education and Research, ChandigarhCirrhotic Cardiomyopathy Based on Point-of-care Echocardiography, Biomarkers and Histology | 2027-10-15 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with cirrhosis patients have a high incidence of sepsis which can trigger decompensation and may result in prolonged hospital stay and increased mortality. About 30%-50% admissions of patients with cirrhosis have sepsis at presentation and about 15% patients admitted to hospital develop sepsis during the hospital stay . After infection develops, the patient may develop acute kidney injury (AKI), shock, encephalopathy or disseminated intravascular coagulation (DIC) further decreasing the chances of survival. In fact, sepsis in patients with cirrhosis is associated with 15% in-hospital mortality, approximately double that of patients without sepsis. So, sepsis is directly responsible for 30-50% of deaths in cirrhosis . Therefore, it is critical to manage sepsis early and appropriately in cirrhosis to reduce the complications and mortality. Early administration of fluids, source control and empirical antibiotics along with vasopressors if refractory shock are essential components of treatment in all patients with sepsis. Currently, the most accepted strategy for early sepsis management is a combination of early goal directed therapy (EGDT) and physiological parameters, such as urine output, lactate clearance, and administration of antibiotics, within 1 hour of presentation . The use of central venous pressure assessment is fallacious for gauging adequacy of fluid resuscitation in cirrhosis, and the difficulty of performing echocardiographic assessments in the setting of ascites and cirrhotic cardiomyopathy is also well described .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20% Albumin in a dose of 20-40 gm per day as infusion over 12-24 h
Drug: 20% albumin · Drug: Balanced salt solution
Fluid resuscitation protocol includes use of an immediate 500 ml bolus of crystalloid i.e., balanced salt solution (BSS) or 0.9% normal saline (Rescue phase), followed by 20 ml/kg fluid in the first 6 hours titrated to target MAP of \> 65mmHg.The second phase of fluid resuscitation (Optimization phase) will be performed as per IVC targets, attainment of lactate clearance, and LUS score to prevent overload.
Drug: Balanced salt solution
Albumin arm for resuscitation fluid
Drug pages: Sodium ChlorideStudies of Sodium ChlorideSodium Chloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Potassium ChlorideStudies of Potassium ChloridePotassium Chloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Calcium ChlorideStudies of Calcium ChlorideCalcium Chloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Magnesium ChlorideStudies of Magnesium ChlorideMagnesium Chloride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Sodium AcetateStudies of Sodium AcetateSodium Acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Sodium CitrateStudies of Sodium CitrateSodium Citrate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Only Balanced salt solution will be used.
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess IVC dynamics.
To compare the IVC dynamics in patients with cirrhosis and sepsis induced hypotension
Time frame: At enrolment
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess IVC dynamics.
To compare the IVC dynamics in patients with cirrhosis and sepsis induced hypotension
Time frame: At 6 hours
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess IVC dynamics.
To compare the IVC dynamics in patients with cirrhosis and sepsis induced hypotension
Time frame: At 24 hours
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess IVC dynamics.
To compare the IVC dynamics in patients with cirrhosis and sepsis induced hypotension
Time frame: At 48 hours.
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess dynamic changes in cardiac output, stroke volume and E/e' echocardiographic parameters.
To compare the cardiac output in patients with cirrhosis and sepsis induced hypotension
Time frame: At enrolment
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess dynamic changes in cardiac output, stroke volume and E/e' echocardiographic parameters.
To compare the cardiac output in patients with cirrhosis and sepsis induced hypotension
Time frame: At 24 hours
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess dynamic changes in cardiac output, stroke volume and E/e' echocardiographic parameters.
To compare the cardiac output in patients with cirrhosis and sepsis induced hypotension
Time frame: At 48 hours.
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)
To compare the new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)in patients with cirrhosis and sepsis induced hypotension
Time frame: At enrolment
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension and assess new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)
To compare the new onset of hepatorenal syndrome (HRS) or acute kidney injury (AKI)in patients with cirrhosis and sepsis induced hypotension
Time frame: At 48 hours.
Urinary marker of AKI (NGal)
Time frame: At enrolment
Change in urinary markers of AKI (NGal)
Time frame: At 24 hours.
Change in urinary markers of AKI(NGal)
Time frame: At 48 hours.
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension., and assess vasopressor requirement
To compare the vasopressor requirement in patients with cirrhosis and sepsis induced hypotension
Time frame: At enrolment
To compare the efficacy of 20% Albumin vs Plasmalyte in the first 3 -6 hours of volume resuscitation in cirrhosis with sepsis induced hypotension., and assess vasopressor requirement
To compare the vasopressor requirement in patients with cirrhosis and sepsis induced hypotension
Time frame: At 24 hours
Started Aug 2020 (actual). Primary completion is estimated for Oct 2028, 98 months after the start.
Of 36 phase 4 interventional studies under Liver Cirrhosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 13. This study's planned 98 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Oct 2023 → Oct 2028 and completion Dec 2023 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumins
Post Graduate Institute of Medical Education and Research, Chandigarh →